Marrow Transplantation Overview

Principles

Definition

Marrow transplantation is a complex medical procedure within the field of cellular therapies. It involves replacing a patient's damaged or diseased bone marrow with healthy hematopoietic stem cells, often following myeloablative therapy. As a research concept, it investigates the mechanisms of hematopoietic reconstitution, immune system recovery, graft-versus-host disease, infection prevention and treatment, and strategies to expand its application for various malignant and non-malignant hematological and immunological disorders. Its significance lies in its potential as a curative therapeutic modality for life-threatening conditions by restoring normal blood cell production and immune function.

Ontological type

Graft-versus-Host Disease Management

Indications and Contraindications

Donor Selection and Matching

Key developments

Key Figures

Conditioning and Immune Foundations era

E. Donnall Thomas[1] conducted work across Washington University in St. Louis[3] and the University of Washington[4] during this era. Thomas[1] contributed the 1974 paper CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,S[6], which documented graft-versus-host disease in HL-A matched sibling marrow recipients and highlighted GVHD as a central barrier to engraftment, influencing donor selection and post-transplant care in this era. E. Donnall Thomas[2] was associated with Stanford University[5] and the University of Washington[4] in this period. Thomas[2] contributed major advances through his 1979 Marrow Transplantation for Acute Nonlymphoblastic Leukemia in First Remission[7], his 1986 Cytomegalovirus Immune Globulin and Seronegative Blood Products to Prevent Primary Cytomegalovirus Infection after Marrow Transplantation[8], and his 1977 Treatment of aplastic anemia by marrow transplantation from HLA identical siblings: Prognostic factors associated with graft versus host disease and survival[9], collectively advancing conditioning and immune foundations through improved patient selection, infection prophylaxis, GVHD understanding, and survival prognostication in this era.

Graft Diversification and Engineering era

Katarina Le Blanc [1], affiliated with Karolinska Institutet [3] and Boston University [4], emerged as a leading figure in graft diversification and mesenchymal stromal cell research during this era. Her contributions include defining minimal criteria for multipotent mesenchymal stromal cells [7], demonstrating the potential of third-party haploidentical mesenchymal stem cells to treat severe acute graft-versus-host disease [8], and reporting on mesenchymal stem cells for steroid-resistant, severe, acute graft-versus-host disease in a phase II study [9], which collectively shaped early clinical deployment and safety frameworks. Darwin J. Prockop [2], with Johns Hopkins University [5] and the University of Pennsylvania [6], was a foundational voice shaping MSC biology and translational approaches during this period. His work includes co-authoring the Minimal criteria for defining multipotent mesenchymal stromal cells [7] and the 1999 paper on transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta [10], which helped define MSC characteristics and explore their clinical potential in genetic disorders.

Immune Engraftment Engineering era

Richard T. Maziarz [1] has been associated with Stanford University [3] and the University of Pennsylvania [4] as a leading figure in post-transplant immunology and hematopoietic cell transplantation during this era. His key contributions include the paper Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes [6], which compared conditioning regimens and helped expand conditioning options in this precision-engraftment era; Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome [7], which highlighted age-related risk and guided age-tailored approaches; and the Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti–T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease–Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation [8], which demonstrated GVHD mitigation strategies. Mary M. Horowitz [2] has worked with Johns Hopkins University [5] and the University of Pennsylvania [4] during this era, contributing to translational hematopoietic cell transplantation research. Her contributions include the Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes [6], and the Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis [9], which informed conditioning decisions and the importance of graft source in expanding donor options in this era.